Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Cash from Financing Activities (2016 - 2025)

Arrowhead Pharmaceuticals (ARWR) has disclosed Cash from Financing Activities for 16 consecutive years, with -$14.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Financing Activities fell 171.48% year-over-year to -$14.8 million, compared with a TTM value of $38.6 million through Dec 2025, down 95.66%, and an annual FY2025 reading of $74.0 million, down 91.5% over the prior year.
  • Cash from Financing Activities was -$14.8 million for Q4 2025 at Arrowhead Pharmaceuticals, down from $3.7 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $430.8 million in Q1 2024 and bottomed at -$42.7 million in Q2 2025.
  • Average Cash from Financing Activities over 5 years is $62.7 million, with a median of $2.3 million recorded in 2021.
  • The sharpest move saw Cash from Financing Activities surged 82741.73% in 2024, then plummeted 184.7% in 2025.
  • Year by year, Cash from Financing Activities stood at $1.9 million in 2021, then surged by 13193.16% to $250.6 million in 2022, then plummeted by 99.89% to $267000.0 in 2023, then soared by 7628.09% to $20.6 million in 2024, then plummeted by 171.48% to -$14.8 million in 2025.
  • Business Quant data shows Cash from Financing Activities for ARWR at -$14.8 million in Q4 2025, $3.7 million in Q3 2025, and -$42.7 million in Q2 2025.